Author

P. Van Vlierberghe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Organism:human· 7 Research Focus:cell type annotation· 5 Approach:statistical model· 5 Assay:ChIP-seq· 4 Research Focus:drug response / drug discovery· 4 Assay:proteomics· 4 Assay:bulk RNA-seq· 3

Frequent Co-Authors

E. Sanders· 3 shared F. Speleman· 3 shared F. Van Nieuwerburgh· 3 shared J. Roels· 3 shared S. Loontiens· 3 shared W. Van Loocke· 3 shared A. Eggermont· 2 shared A. Louwagie· 2 shared

Activity by Year

2018-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Sanders

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

The fork restart factor PHF6 interacts with RRM2 and binds to H3K56ac marked nascent DNA

L. Depestel, S.-L. Bekaert, E. Sanders, C. Van Damme, A. Eggermont, S. Loontiens, L. Tilleman, F. Van Nieuwerburgh, L. Delhaye, P. Van Vlierberghe, S. Eyckerman, F. Speleman, K. Durinck

This study identifies PHF6's interaction with RRM2 and its binding to H3K56ac marked nascent DNA, revealing a role in replication fork restart and DNA damage repair.

bioRxiv · Mar 8, 2023 · PreprintCancer Biology

An interactive mass spectrometry atlas of histone posttranslational modifications in T-cell acute leukemia

L. Provez, B. Van Puyvelde, L. Corveleyn, N. Demeulemeester, S. Verhelst, B. Lintermans, S. Daled, J. Roels, L. Clement, L. Martens, D. Deforce, P. Van Vlierberghe, M. Dhaenens

The paper presents a comprehensive mass spectrometry-based atlas of histone posttranslational modifications in T-cell acute lymphoblastic leukemia cell lines, providing a reusable dataset for epidrug development.

bioRxiv · May 5, 2022Cancer Biology

The transcription factor RUNX2 drives the generation of human NK cells and promotes tissue residency

S. Wahlen, F. Matthijssens, W. Van Loocke, S. Taveirne, L. Kiekens, E. Persyn, E. van Ammel, Z. De Vos, S. De Munter, P. Matthys, F. Van Nieuwerburgh, T. Taghon, B. Vandekerckhove, P. Van Vlierberghe, G. Leclercq

This study shows that RUNX2 promotes human NK cell generation and tissue residency through IL-2Rβ induction, with implications for cancer therapy.

bioRxiv · May 2, 2022Immunology

Engraftment of allotransplantated tumour cells in adult rag2 mutant Xenopus tropicalis

D. Tulkens, D. Dimitrakopoulou, T. Van Nieuwenhuysen, M. Boelens, S. Demuynck, W. Toussaint, D. Creytens, P. Van Vlierberghe, K. Vleminckx

This paper establishes a Xenopus tropicalis model for studying human cancer by generating a rag2-/- knock-out line and optimizing irradiation protocols for tumor cell engraftment.

bioRxiv · Nov 15, 2021 · PreprintCancer Biology

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma

C. Nunes, L. Depestel, L. M. Mus, K. M. Keller, L. Delhaye, A. Louwagie, M. Rishfi, E. M. Dolman, V. Olexiouk, C. Bartenhagen, F. Devloed, E. Sanders, A. Eggermont, J. Van Laere, E. De Smet, , F. Speleman

This study identifies RRM2 as a therapeutic target in high-risk neuroblastoma, showing that combined RRM2 and CHK1 inhibition synergistically reduces tumor growth.

bioRxiv · Nov 25, 2020 · PreprintCancer Biology

Exostosin-1 Glycosyltransferase Regulates Endoplasmic Reticulum Architecture and Dynamics

D. Kerselidou, B. S. Dohai, D. R. Nelson, S. Daakour, N. De Cock, D.-K. Kim, J. Olivet, D. C. El Assal, A. Jaiswal, D. Saha, C. Pain, F. Matthijssens, P. Lemaitre, M. Herfs, J. Chapuis, , J.-C. Twizere

This study shows that Exostosin-1 glycosyltransferase regulates ER morphology and dynamics, affecting cell size and metabolic processes in mammalian cells.

bioRxiv · Sep 2, 2020 · PreprintCell Biology

SOX11 is a lineage-dependency factor and master epigenetic regulator in neuroblastoma

B. Decaesteker, A. Louwagie, S. Loontiens, F. De Vloed, J. Roels, S. Vanhauwaert, S. De Brouwer, E. Sanders, G. Denecker, E. D'haene, S. Van Haver, W. Van Loocke, J. Van Dorpe, D. Creytens, N. Van Roy, , F. Speleman

This study identifies SOX11 as a critical transcription factor and epigenetic regulator in adrenergic neuroblastoma, showing its role in chromatin accessibility and cell identity.

bioRxiv · Aug 21, 2020 · PreprintCancer Biology

Single cell profiling of immature human postnatal thymocytes resolves the complexity of intra-thymic lineage differentiation and thymus seeding precursors.

M. Lavaert, K. L. Liang, N. Vandamme, J.-E. Park, J. Roels, M. S. Kowalczyk, B. Li, O. Ashenberg, M. Tabaka, D. Dionne, T. L. Tickle, M. Slyper, O. Rozenblatt-Rosen, B. Vandekerckhove, G. Leclercq, , T. Taghon

The paper uses single-cell RNA sequencing to analyze immature human thymocytes and identifies thymus seeding precursors and T-lineage developmental pathways.

bioRxiv · Apr 7, 2020 · PreprintImmunology

Dynamic 3D chromosomal landscapes in acute leukemia

A. Kloetgen, P. Thandapani, P. Ntziachristos, Y. Ghebrechristos, S. Nomikou, C. Lazaris, X. Chen, H. Hu, S. Bakogianni, J. Wang, Y. Fu, F. Boccalatte, H. Zhong, E. Paietta, T. Trimarchi, , A. Tsirigos

The paper examines 3D chromatin changes in T-ALL, identifies TAD fusion events linked to oncogene activation, and shows drug treatments can restore some interactions.

bioRxiv · Aug 4, 2019Cancer Biology

USP7 cooperates with NOTCH1 to drive the oncogenic transcriptionalprogram in T cell leukemia

P. Ntziachristos, K. Arcipowski, Q. Jin, C. A. Martinez, Y. Zhu, B. T. Gutierrez Diaz, K. Wang, M. Johnson, A. G. Volk, F. Wang, J. wu, H. Wang, I. Sokirniy, P. Thomas, Y. A. Goo, , J. D Crispino

This study identifies USP7 as a key driver of T-cell leukemia by stabilizing NOTCH1 and JMJD3, showing USP7 inhibition blocks leukemia growth and suggests it as a therapeutic target.

bioRxiv · Jan 16, 2018Cancer Biology